Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial - de Botton, S; Montesinos, P; Schuh, AC; Papayannidis, C; Vyas, P; Wei, AH; Ommen, H; Semochkin, S; Kim, H-J; Larson, RA; Koprivnikar, J; Frankfurt, O; et al. (Blood, 2022)